Immunocore Holdings plc
IMCRNasdaq
$34.96
↑ +1.4%Jul 17 close · end-of-day
Price
1Y↓ -2.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.9B
Enterprise Value
$1.0B
P/E
—
P/S
4.5
P/B
4.7
EV/EBITDA
—
PEG
—
FCF Yield
-1.7%
Dividend Yield
—
Revenue (TTM)
$412.8M
Net Income (TTM)
-$27.6M
Free Cash Flow (TTM)
-$30.7M
Gross Margin
—
Operating Margin
-8.3%
Net Margin
-6.7%
ROE
-7.0%
ROIC
—
Debt / Equity
—
Net Cash
$844.9M
Return 1Y
-3.5%
Company profile
Immunocore Holdings plc engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. KIMMTRAK is in Phase I/II trials for patients with unresectable or metastatic uveal melanoma. The company's programs for infectious diseases include IMC-I109V, which is in a clinical trial in patients with chronic hepatitis B virus.
- CEO
- Bahija Jallal
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 320
- Website
- immunocore.com
Management & directors
- Berman David MHEAD OF R&D
- Goll JohnSVP, FINANCE & CAO
- Jallal BahijaCHIEF EXECUTIVE OFFICER
- St Leger Tina AmberCHIEF HR OFFICER
Roles derived from SEC Form 4 filings.
Earnings
IMCR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$106.7M↑ +13.6%
Diluted EPS$0.25↑ +150.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $36.5M | $174.4M | $249.4M | $310.2M | $400.0M |
| Gross profit | — | — | — | — | — |
| Operating income | -$174.6M | -$51.7M | -$59.6M | -$70.5M | -$45.4M |
| Net income | -$180.0M | -$52.5M | -$55.3M | -$51.1M | -$35.5M |
| Diluted EPS | -$4.24 | -$1.15 | -$1.13 | -$1.02 | -$0.71 |
| Operating cash flow | -$143.1M | -$49.2M | $2.9M | $26.1M | -$10.7M |
| Free cash flow | -$144.5M | -$51.4M | -$2.5M | $20.9M | -$15.1M |
| Gross margin | — | — | — | — | — |
| Operating margin | -478.5% | -29.7% | -23.9% | -22.7% | -11.3% |
| Net margin | -493.4% | -30.1% | -22.2% | -16.5% | -8.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $75.4M | $80.2M | $84.1M | $93.9M | $98.0M | $103.7M | $104.5M | $106.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$16.0M | -$8.5M | -$19.5M | -$3.6M | -$14.9M | -$7.2M | -$19.7M | $7.3M |
| Net income | -$11.6M | $8.7M | -$23.8M | $5.0M | -$10.3M | -$177,000.00 | -$30.1M | $13.0M |
| Diluted EPS | -$0.23 | $0.17 | -$0.47 | $0.10 | -$0.20 | $0.00 | -$0.61 | $0.25 |
| Operating cash flow | $23.5M | $21.1M | -$14.0M | $435,000.00 | $26.0M | -$4.5M | -$32.7M | -$13.8M |
| Free cash flow | $23.1M | $20.3M | -$17.5M | $137,000.00 | $25.6M | -$5.2M | -$35.5M | -$15.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -21.2% | -10.6% | -23.1% | -3.9% | -15.2% | -6.9% | -18.8% | 6.8% |
| Net margin | -15.4% | 10.9% | -28.3% | 5.4% | -10.5% | -0.2% | -28.8% | 12.2% |
Company news
Jul 7, 2026
Jul 6, 2026
Jul 3, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-02-18 | Jallal Bahija· CHIEF EXECUTIVE OFFICER | Sale | 11,474 | $32.35 | $371,183.90 | filing |
| 2026-02-18 | Berman David M· HEAD OF R&D | Sale | 5,965 | $32.35 | $192,967.75 | filing |
| 2026-02-18 | St Leger Tina Amber· CHIEF HR OFFICER | Sale | 1,000 | $32.35 | $32,350.00 | filing |
| 2026-02-18 | GOLL JOHN· SVP, FINANCE & CAO | Sale | 698 | $32.35 | $22,580.30 | filing |
| 2026-02-17 | St Leger Tina Amber· CHIEF HR OFFICER | Option exercise | 2,119 | $0.00 | $0.00 | filing |
| 2026-02-17 | Jallal Bahija· CHIEF EXECUTIVE OFFICER | Option exercise | 23,817 | $0.00 | $0.00 | filing |
| 2026-02-17 | GOLL JOHN· SVP, FINANCE & CAO | Option exercise | 1,351 | $0.00 | $0.00 | filing |
| 2026-02-17 | Berman David M· HEAD OF R&D | Option exercise | 11,824 | $0.00 | $0.00 | filing |
| 2025-12-05 | Berman David M· HEAD OF R&D | Sale | 572 | $40.14 | $22,960.08 | filing |
| 2025-12-05 | Berman David M· HEAD OF R&D | Option exercise | 572 | $17.46 | $9,987.12 | filing |
| 2025-12-04 | Berman David M· HEAD OF R&D | Sale | 31,341 | $40.26 | $1.3M | filing |
| 2025-12-04 | Berman David M· HEAD OF R&D | Option exercise | 31,341 | $17.46 | $547,213.86 | filing |
| 2025-11-28 | Berman David M· HEAD OF R&D | Sale | 5,521 | $40.09 | $221,336.89 | filing |
| 2025-11-28 | Berman David M· HEAD OF R&D | Option exercise | 5,521 | $17.46 | $96,396.66 | filing |
| 2025-11-26 | Berman David M· HEAD OF R&D | Sale | 69,404 | $40.12 | $2.8M | filing |
| 2025-11-26 | Berman David M· HEAD OF R&D | Option exercise | 69,404 | $17.46 | $1.2M | filing |
| 2025-11-25 | Berman David M· HEAD OF R&D | Sale | 18,020 | $40.03 | $721,340.60 | filing |
| 2025-11-25 | Berman David M· HEAD OF R&D | Option exercise | 18,020 | $17.46 | $314,629.20 | filing |
| 2025-11-24 | Berman David M· HEAD OF R&D | Sale | 100 | $40.00 | $4,000.00 | filing |
| 2025-11-24 | Berman David M· HEAD OF R&D | Option exercise | 100 | $17.46 | $1,746.00 | filing |
| 2025-09-30 | Berman David M· HEAD OF R&D | Sale | 61,849 | $35.23 | $2.2M | filing |
| 2025-09-30 | Berman David M· HEAD OF R&D | Option exercise | 61,849 | $17.46 | $1.1M | filing |
| 2025-09-15 | Berman David M· HEAD OF R&D | Sale | 200 | $35.01 | $7,002.00 | filing |
| 2025-09-15 | Berman David M· HEAD OF R&D | Option exercise | 200 | $17.46 | $3,492.00 | filing |
| 2025-09-12 | Berman David M· HEAD OF R&D | Sale | 21,232 | $35.63 | $756,496.16 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.